Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Sunitinib, and WBRT for Breast Cancer CNS Metastases
NCT00570908Phase 2Terminated
- Sponsor
- Baylor Breast Care Center
- Start
- Feb 2009
- Primary completion
- Sep 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, capecitabine in breast cancer, sponsored by Baylor Breast Care Center. Started Feb 2009; status: terminated.
02
Drugs
sunitinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00570908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570908.